comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 00:35:36 - browse：589

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

WSS

The lessons of Aduhelm, an Alzheimer's drug that was not to be

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Commercial surrogacy can be ethical, despite pope’s claims

Quicker fix for pulse oximeters urged during FDA public meeting

Scientists grapple with ethics of stem cell research

Cognito secures funding to test medical device for Alzheimer's

knowledge

comprehensive

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Hormonal contraceptives don’t actually treat endometriosis

Dobbs anniversary: the lost opportunity of abortion as health care

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A $475,000 price tag for a new cancer drug: crazy or meh?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Dementia risk linked to living in disadvantaged areas: Study

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How a Boston hospital is priming medical residents to use GPT

hotspot

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Cognito secures funding to test medical device for Alzheimer's

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Do digital therapeutics have a future in medicine?

Novo Nordisk to expand supply of Wegovy for U.S. patients

A $475,000 price tag for a new cancer drug: crazy or meh?

hotspot

explore

knowledge

Wikipedia